🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#MeetTheExpert Zohar Gadri, MSc—Scinai’s Process Development and Optimization lead with 13 years in protein purification and GMP production! His expertise ensures that Scinai’s robust production meets the demands of modern drug development. $SCINAI #Biopharmaceuticals

Transitioning a #molecule from academia to commercial #pharma requires shifting from exploration to scalability. Find expert insights on managing the molecule selection process and planning for scalability in Scinai Immunotherapeutics Ltd User’s Guide to Drug Development >> scinai.com/cdmo-lp-ebook

Scinai Immunotherapeutics Ltd reports strengthened Q3 2024 financials, achieving $10M in positive shareholder equity following the €26.6M EIB loan-to-equity conversion. Initial revenues for #CDMO Business Unit. R&D efforts progressed with promising psoriasis data and new licensing opportunities. Read

🚨 Big News! 🚨 We’re thrilled to announce that Dr. Jonathan Sadeh, former SVP of Immunology R&D at Bristol-Myers Squibb, has joined Scinai's Scientific Advisory Board! Read more on: scinai.com/press-releases… $SCNI #AdvisoryBoard Amir Reichman

Proud to welcome Hopec Pharma to Scinai Immunotherapeutics Ltd #CDMO #BioServices. We’ll manufacture their groundbreaking UPEC-FimON immunotherapy and support clinical trial readiness, ensuring a seamless path to patients. Together, we’re shaping the future of bladder cancer treatment. Thank you for

#Announcement #AdvisoryBoard We’re excited to welcome Prof. Michael Schön, Director of Dermatology at UMG, to the Scinai Immunotherapeutics Ltd Scientific Advisory Board! With his exceptional expertise in #immunotherapy and #dermatology, Prof. Schön will play a key role in advancing our innovative

Congrats to Dr. Jonathan Sadeh, Scinai Immunotherapeutics Ltd Scientific Advisory Board member, on becoming CSO & CMO of Bausch Health! Proud to have such a high-caliber talent advising our R&D team and board of directors $SCNI

Scinai Bioservices is now in the U.S.! 🇺🇸 Thrilled to launch Scinai Immunotherapeutics Ltd Delaware-based #CDMO subsidiary and kick off with our first U.S. client, Serpin Pharma. #Growth ahead! 🚀 #Biotech $SCNI

🚀 Scinai is headed to IATI #MiniMixiii, J.P. Morgan #JPM2025, & #SIC Biotech! Let’s talk #PharmaPartnering, #CDMO, & investment. 💡 Email: [email protected]. Amir Reichman #BioTechInnovation

2024 was a game-changer for Scinai! 🚀 From $29M debt-to-equity conversion to R&D breakthroughs, we’ve made incredible strides. 🎥 Watch the video for key highlights from our CEO and get ready for what’s next at #JPM2025! $SCNI #Scinai #Biotech #NanoAbs #CDMO #Innovation

Excited to see Hopec Pharma, based on Prof. Ofer Mandelboim’s research (Hebrew University), featured in Scinai Immunotherapeutics Ltd’s Customer Spotlight! Their UPEC-FimON immunotherapy offers a promising, targeted, and less burdensome treatment for NMIBC.

🚀 Big news! Our CEO, Amir Reichman, is speaking at #MIXiii Health-Tech.IL 2025! Hear about our journey from near closure to leading biotech I&I innovator. Thanks for recognizing Scinai Immunotherapeutics Ltd as a top Jerusalem startup to present at the congress! $SCNI #biotech #speaker

Scinai Immunotherapeutics Ltd signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions. $SCNI

🎥 THRILLED to share a preview of our partnership with Pincell srl and their breakthrough antibody PC111, targeting severe skin diseases via the Fas/FasL pathway. 🧬 Join our upcoming Scinai x Pincell event on May 7th at 11:30am ET to learn how we're advancing safer, more

ICYMI: Last week, Scinai hosted an investor webinar highlighting their partnership with PinCell and the option agreement to acquire their monoclonal antibody for the development of rare skin diseases. Missed the event? Check out the full webinar now! register.scinai.com/eventdetails

Is our new skin disease drug set up for an acquisition by Pharma? Listen in below as Jonathan Sadeh, M.D., Executive Vice President, Head of R&D and CMO, at Bausch Health, details why there is much excitement around this asset for rare skin diseases and how the niche nature of

Scinai Immunotherapeutics Ltd is reshaping immunotherapy with de-risked antibody platforms for autoimmune & inflammatory diseases.🎥 Watch CEO Amir Reichman share our vision, pipeline & what’s next. 📍 Meet us at #BiomedIsrael2025 & #BIO2025! $SCNI #growth #innovation #biotech

🎥 Two De-risked Pipeline Assets. One Scalable Platform. In this 60-second video, Scinai CEO Amir Reichman shares how Scinai Immunotherapeutics is advancing: 🔹 A differentiated nanobody platform for autoimmune diseases, which offers several advantages in clinical development

Scinai Immunotherapeutics Ltd (Nasdaq: $SCNI) kicks off 2025 with strong momentum. Q1 CDMO revenues hit $586K—nearly matching all of 2024—driven by more contracts and rising demand. Cash burn cut nearly 50% YoY, reflecting efficient growth across our CDMO and I&I pipeline. #CDMO #Biotech #Growth

🎥 Video Out Now: Why Q1 2025 Marked a Breakthrough for Scinai 📈 ICYMI: We’re excited to share this quick video capturing a standout Q1 for Scinai and our team’s momentum: 🔹 CDMO revenue surged – $586K in Q1, already approaching our full‑year 2024 🔹 Streamlined expenses –